

# Clinical Policy Advisory Group (CPAG)

## CPAG DECISION MAKING DURING THE COVID PANDEMIC

### CPAG DECISION MAKING DURING THE COVID PANDEMIC – Updated November 2020

Due to the current Covid-19 pandemic an interim CPAG Terms of Reference (ToR) has been devised to ensure that there is continuity of CPAG meetings during these extraordinary times. The interim arrangements can be found on the Derby and Derbyshire CCG (DDCCG) Clinical Policies website: <a href="http://www.derbyshiremedicinesmanagement.nhs.uk/assets/Clinical-policies/CPAG/CPAG TOR/interim\_cpag\_tor.pdf">http://www.derbyshiremedicinesmanagement.nhs.uk/assets/Clinical-policies/CPAG/CPAG TOR/interim\_cpag\_tor.pdf</a>

## **PRIOR APPROVAL UPDATED**

Prior Approval (PA) is an assurance mechanism used by DDCCG to ensure that the clinical criteria listed within the Procedures of Limited Clinical Value (PLCV) policies are met. Through CPAG, DDCCG has collaborated with stakeholders to remove any unnecessary administration burden.

A useful summary can be found on the DDCCG Clinical Policies website: <u>http://www.derbyshiremedicinesmanagement.nhs.uk/clinical-policies-home/clinical-policies/plcv</u>

## CLINICAL POLICIES UPDATED PROCEDURES OF LIMITED CLINICAL VALUE POLICIES

Research evidence shows that some interventions are not clinically effective or only effective when they are performed in specific circumstances. The purpose of the Procedures of Limited Clinical Value (PLCV) policy is to clarify the commissioning intentions of the Clinical Commissioning Group (CCG). The CCG will only fund treatment for clinically effective interventions that are then delivered to the right patients.

#### No updates this month.

<b>'NEW' NOT ROUTINELY COMMISSIONED - POSITION STATEMENTS</b>		
Statement	Description	
Laser treatment for Myopia	Laser eye surgery (LASIK) is a form of treatment for short-sight, long-sight and astigmatism.	
Reversal of female sterilisation	Reversal of female sterilisation is a surgical procedure that involves the reconstruction of the fallopian tubes.	
Reversal of male sterilisation	Vasectomy reversal is surgery to undo a vasectomy. It reconnects each tube (vas deferens) that carries sperm from a testicle into the semen	
CLINICAL POLICIES UPDATED: SUMMARY OF POLICIES		
Clinical Policy	Key Changes	
Benign Skin Lesion Policy – Anal Skin Tags	A skin tag is a noncancerous growth of excess skin. Skin tags that form around the anus or rectum are called anal skin tags. The Anal Skin Tag "do not do" commissioning statement has been removed from the Clinical Policies website. <b>New</b> The Benign Skin Lesion Policy has been updated to include removal of large inflamed and painful Anal Skin Tags	
Functional Electrical Stimulation (FES)	Functional electrical stimulation (FES) is a treatment that applies small electrical charges to a muscle that has become paralysed or weakened, due to damage in your brain or spinal cord. The electrical charge stimulates the muscle to make its usual movement. The policy has been streamlined and aligned to the DDCCG clinical policies format.	
Definition of "functional" to be included in relevant cosmetic policies	An overarching clinical definition of "functional" will be included in the CCGs cosmetic policies for to the following procedures: <ul> <li>Abdominoplasty</li> <li>Breast Reduction</li> <li>Scar Reduction</li> <li>Lipoma</li> </ul> <li>Definition of Functional <ul> <li>The aim of surgery is to improve patient function relating to a diagnosed pathology which has been clinically defined as resulting from a tissue state which can be addressed through Plastic Surgery procedures"</li> </ul></li>	

#### CPAG WEBSITE DEVELOPMENT & ELECTRONIC REFERRAL SERVICE TEMPLATES

The Electronic Referral Service (ERS) PLCV referral form templates are being reviewed and updated to accurately reflect the current policies and are now available on the Clinical policies website. We actively encourage feedback which should be sent to the PLCV inbox at <u>PLCV.priorapproval@nhs.net</u>

### NICE INTERVENTIONAL PROCEDURES GUIDANCE, DIAGNOSTIC PROCEDURES, MEDICAL TECHNOLOGIES GUIDANCE AND MEDTECH INNOVATION BRIEFINGS (IPGS, DTG, MTGS, MIBS)

The DDCCG does not commission and will not fund any procedure or technology assessed by NICE under their IPG, MTG, DTG and MIB programmes unless:

 the provider has submitted a robust, evidenced based business case to the commissioner and this has been subsequently approved AND

- · the NICE IPG states 'use with standard arrangements for clinical governance, consent and audit'
- OR the NICE MTG states 'the case for adoption within the NHS as described is supported by the evidence'
- OR the NICE DTG makes a recommendation as an option for use
- OR the NICE MIB has evaluated the innovation.

The following NICE programme outputs were noted by the group for the month of November:

IPG/MTG/DTG/MIB	Description	Outcome
IPG684	Swallowable gastric balloon capsule for weight loss	Research only – not commissioned
MIB232	KardiaMobile for the ambulatory detection of atrial fibrillation	Not commissioned without the provider submitting a robust, evidenced based business case to the commissioner and subsequent approval
MIB233	Dexcom G6 for real-time continuous glucose monitoring	Not commissioned without the provider submitting a robust, evidenced based business case to the commissioner and subsequent approval
MIB234	ClearGuard HD Antimicrobial Barrier Cap for preventing haemodialysis catheter-related bloodstream infections	Not commissioned without the provider submitting a robust, evidenced based business case to the commissioner and subsequent approval
MIB235	NPi-200 for pupillary light reflex in critical care patients	Not commissioned without the provider submitting a robust, evidenced based business case to the commissioner and subsequent approval
MIB236	Temporarily withdrawn	
MIB237	QuickChange Incontinence Wrap for urinary incontinence in men	Not commissioned without the provider submitting a robust, evidenced based business case to the commissioner and subsequent approval

Our CCG continues to monitor and implement IPGs with our main providers.

## NHS ENGLAND INNOVATION AND TECHNOLOGY PAYMENTS (ITP)

The DDCCG have no statutory duty to fund the additional costs associated with the implementation of NHS England's Innovation and Technology Payment innovations.